You may have seen me or Rob Smith blogging about shared value and how it’s the wave of the future for corporate responsibility. And you may have thought, “OK, Sounds good. But why the heck do they keep going on about it?”
Well, here’s why: today we announced The Lilly NCD Partnership, a new program we’ve been developing for almost a year that epitomizes shared value. Lilly is investing $30 million over five years to fight the rising burden of non-communicable diseases in developing countries – diseases such as diabetes, cancer and cardiovascular diseases. Our initial focus will be on diabetes, an area in which there is great global need for new approaches – and in which we have over 80 years of experience, knowledge and passion.
We are partnering with leading global health organizations to identify comprehensive new approaches to improving diabetes care for people who often go untreated or don’t receive proper treatment for a myriad of reasons. With our partners, we will research and test new models of patient care; report the results of these pilots—including what worked and what didn’t; and advocate for the adoption and replication of the best, most cost-effective solutions. This comprehensive approach will help inform decisions by the global health community, including governments and key stakeholders, on how best to invest limited resources to address diabetes in underserved populations.
In the end, it’s about improving individual people’s lives, which has ripple effects on families, communities, nations and, dare we hope, even the world.
And it’s about making Lilly a better company. Throughout this partnership, we will have our eyes, ears and minds open – looking for new ways to do things, new ways to meet people’s needs, new ways of working with others who are looking for solutions.